Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

ATR-04 is in development for epidermal growth factor receptor inhibitor -induced dermal toxicity, which affects approximately 150,000 patients in the US



Reduces methicillin-resistant S. aureus by...

Related Keywords

Dallas ,Texas ,United States ,American ,Travis Whitfill ,Society Of Investigative Dermatology ,Azitra Inc ,Investigative Dermatology ,Investigational New Drug ,Private Securities Litigation Reform Act ,